enGene Therapeutics develops genetic medicines, led by detalimogene, a product candidate for a type of bladder cancer. It last closed at $1.74 on Nov 20, down 1.14% on the day. The next earnings report for ENGN is expected around Mon, Mar 8, 2027. For the quarter ended Jul 2026, ENGN reported EPS of -$0.47. Over its last 8 reports the stock moved an average of 9.2% the session after earnings. Over the last 12 months ENGN insiders bought $10K of stock on the open market and sold $0, according to SEC Form 4 filings.
AI Auto Pilots
Is ENGN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ENGN.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on ENGNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
ENGN · as of the Nov 20 close · updated each morning
Moving sideways
The stock is 0% below its 20 day and 3% below its 50 day average. It is 116% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 49). The nearest support is the swing low (Jul 29) at $1.71, and the nearest resistance the swing high (Oct 16) at $1.75.
Short trendNeutral
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 10.7%/day
Key levels
$12.2552 week high+604.0%
$3.75200 day average+115.5%
$1.81100 day average+4.0%
$1.80Pivot R1+3.4%
$1.7950 day average+2.9%
$1.75Swing high (Oct 16)+0.6%
$1.7420 day average+0.0%
$1.74Pivot+0.0%
$1.74Last close
$1.71Swing low (Jul 29)−1.7%
$1.68Pivot S1−3.4%
$1.4052 week low−19.5%
Indicators
RSI (14)
48.64
Middle of its range
Neutral
MACD
0.04
Below its signal line
Bearish
Stochastic
31.4
Middle of its range
Neutral
ADX (14)
22.1
Weak trend
Williams %R
-72.6
Oversold below −80, overbought above −20
Neutral
CCI (20)
-0.3
Oversold below −100, overbought above 100
Neutral
Rate of change
−0.6%
Change over 10 sessions
Bearish
ATR (14)
$0.19
Typical daily range, 10.7% of price
MA 10Below
MA 20Above
MA 50Below
MA 100Below
MA 200Below
Falling
Short trendBearish
Long trendNot enough history
MomentumNeutral
StretchNormal
VolatilityNormal, 28.3%/day
Key levels
$12.2552 week high+604.0%
$3.75200 day average+115.5%
$1.81100 day average+4.0%
$1.80Pivot R1+3.4%
$1.7950 day average+2.9%
$1.75Swing high (Oct 16)+0.6%
$1.7420 day average+0.0%
$1.74Pivot+0.0%
$1.74Last close
$1.71Swing low (Jul 29)−1.7%
$1.68Pivot S1−3.4%
$1.4052 week low−19.5%
Indicators
RSI (14)
39.76
Weak, oversold below 30
Neutral
MACD
-0.59
Above its signal line
Bullish
Stochastic
55.2
Middle of its range
Neutral
ADX (14)
26.6
Trending up
Williams %R
-72.6
Oversold below −80, overbought above −20
Neutral
CCI (20)
63.5
Oversold below −100, overbought above 100
Neutral
Rate of change
−3.3%
Change over 10 sessions
Bearish
ATR (14)
$0.49
Typical daily range, 28.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for ENGN
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ENGN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow ENGN usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for ENGNHow many large options trades hit ENGN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in ENGN in the last 90 days.
From SEC Form 4 filings by ENGN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ENGN is in one of them and how their past ENGN trades turned out.
enGene Therapeutics is a biotechnology company based in Saint-Laurent that develops genetic medicines. Its main product candidate, detalimogene, is intended for patients with a form of bladder cancer that no longer responds to BCG treatment. The company is also building a delivery platform that carries genetic medicines to mucosal tissues, with plans to apply it to other conditions such as urogenital and gastrointestinal diseases. Its products are still in preclinical and clinical development and are not yet approved for sale.